# US 2019/0315642 A1 · Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315642 A1
- Document ID: US20190315642A1
- Status: Published application
- Kind: A1
- Application number: 16/429,474
- Filed: 2019-06-03
- Published: 2019-10-17
- Earliest claimed: 2016-07-27
- Assignees: SynPhaGen LLC
- Applicants: SynPhaGen LLC
- Inventors: Todd Bernard Parsley; Christian Furlan Freguia
- Web page: https://patentgrep.com/patent/US20190315642A1

## CPC

- A61K 38/2066: {IL-10}
- A01N 63/40: Viruses, e.g. bacteriophages
- A61K 38/45: Transferases (2)
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C02F 3/34: characterised by the microorganisms used
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/86: Viral vectors
- C12Y 201/02001: Glycine hydroxymethyltransferase (2.1.2.1)
- C12Y 203/02013: Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
- C02F 3/348: {characterised by the way or the form in which the microorganisms are added or dosed}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/531: Stem-loop; Hairpin
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C12N 2330/50: Biochemical production, i.e. in a transformed host cell
- C12N 2795/00021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2795/00031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2795/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2795/00043: viral genome or elements thereof as genetic vector
- C12N 2795/14143: viral genome or elements thereof as genetic vector
- C12N 2820/55: from bacteria
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- C02F: TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE (separation in general B01D; special arrangements on waterborne vessels of installations for treating water, waste water or sewage, e.g. for producing fresh water, B63J; adding materials to water to prevent corrosion C23F; treating radioactively-contaminated liquids G21F9/04; regeneration of reactants for recirculation into processes, see the relevant places for the processes)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Compositions for a phage particle are disclosed. The phage particle is non-replicating and includes at least one heterologous nucleic acid sequence that is capable of being expressed in a target bacteria. The expressed heterologous nucleic acid sequence is non-lethal to the target bacteria.

## Claims

### Claim at position 1

1-10. (canceled)

### Claim 11 (depends on 26)

The phage particle according to claim 26, wherein the nucleic acid sequence encodes a regulatory RNA sequence such as, but not limited to, shRNA, siRNA, or microRNA.

### Claim at position 3

12-15. (canceled)

### Claim 16 (depends on 26)

The phage particle according to claim 26, wherein the nucleic acid sequence encodes a product capable of remediation of a toxic product in an environment.

### Claim 17 (depends on 26)

The application of the phage particle according to claim 26, wherein the phage particle is applied to waste water or industrial waste or byproduct to decontaminate or detoxify the waste, wherein the phage particle may be co-administered with the target bacteria.

### Claim 18 (depends on 26)

The phage particle according to claim 26, wherein the nucleic acid sequence encodes a product or products capable of metabolism of precursor material to an industrial product.

### Claim 19 (depends on 26)

The application of the phage particle according to claim 26, wherein the phage particle is applied to industrial or environmental material to produce or improve on the production a metabolic product.

### Claim 20 (depends on 26)

The phage particle according to claim 26, wherein the nucleic acid sequence encodes at least one product capable of conferring resistance to a pathogen.

### Claim 21 (depends on 26)

The application of the phage particle according to claim 26, wherein the phage particle is applied to plants or soil for the treatment of a plant pathogen or pest.

### Claim 22 (depends on 26)

The application of the phage particle according to claim 26, wherein the phage particle is applied indirectly or directly to an insect capable of transmission of a pathogen, wherein the phage particle contains at least one gene encoding a product that disrupts a replication cycle of an infectious agent within the insect.

### Claim at position 11

23-25. (canceled)

### Claim 26

A phage particle comprising:
a phagemid including at least one nucleic acid sequence,
an origin of replication necessary for replication of the phagemid in target bacteria and
a receptor binding protein designed to attach, in vivo, to the target bacteria in a non-human microbiome,
wherein the at least one nucleic acid sequence is expressed in the target bacteria and wherein the expression of the at least one nucleic acid sequence is non-lethal to the target bacteria and
wherein a functional gene of the phage particle that sustains phage replication is silenced so that the phage particle is incapable of independent replication.
